FDAnews
www.fdanews.com/articles/179444-european-commission-approves-bristol-myers-squibbs-opdivo

European Commission Approves Bristol-Myers Squibb’s Opdivo

November 28, 2016

The EC approved Opdivo for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin.

The approval is based on an integrated analysis of data from the phase II CheckMate -205 and the Phase I CheckMate -039 trials.

The safety of Opdivo in cHL was evaluated in 263 adult patients from CheckMate -205 and CheckMate -039.

View today's stories